15:26:09 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.


2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-11-11 11:30:00

After a solid process, which was delayed by the pandemic, ChemoTech has now reached a long-awaited milestone by establishing a Centre of Excellence "CoE" at the India Sweden Healthcare Innovation Centre. This Innovation Centre is physically located at the All India Institute of Medical Sciences (AIIMS) Jodhpur and is part of the state cooperation in health care between Sweden and India and is an initiative that is co-financed by the Swedish and Indian states.

This agreement means that AIIMS Jodhpur and ChemoTech, through this CoE, will conduct clinical studies with the aim of creating clinical data and evidence for the effect of TSE treatment on various cancers. The first studies are planned to start during Q2-Q3 2022 and mainly include head andneck cancer, which accounts for approx. 30-40% [1.2] of all cancer cases in India (total number of cancer cases amounts to about 1.4 million cases[3]).

It is of great importance to ChemoTech that AIIMS now chooses to collaborate through the India-Sweden Healthcare Innovation Centre and thereby ensures access to ChemoTech `s technology and the opportunity to gather knowledge in order to build a CoE. ChemoTech will contribute with two IQwave systems. One system shall be dedicated to clinical studies and one for the training of future doctors in medical education, which constitutes an essential part of the institute's activities.

"We are very grateful for the help we have received through the government initiatives; The Embassy of Sweden in Delhi, and Business Sweden who run the Innovation Centre; also Swecare and the Sweden India Business Council have all contributed to this process. For the company, this is a very big step forward, which indicates that the general healthcare system in India also understands the unique opportunities that TSE can contribute to cancer care in India." - says Mohan Frick, CEO of ChemoTech

[1] Manik Rao Kulkarni, IJHNS, 2013;4(1):29-35
[2 ]Bhattacharjee A et al., IJOHNS 2006;58:15-19
[3 ]Mathur P et al., JCO Glob Oncol, 2020;6:1063-1075

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-11-2021 11:30 CET.